Vaxcyte Inc. (PCVX)
82.56
-0.80 (-0.96%)
At close: Feb 20, 2025, 3:59 PM
82.47
-0.10%
After-hours: Feb 20, 2025, 04:00 PM EST
undefined% (undefined)
| Bid | 70.66 |
| Market Cap | 10.29B |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -4.6 |
| PE Ratio (ttm) | -17.95 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 84.84 |
| Volume | 476,071 |
| Avg. Volume (20D) | 1,097,057 |
| Open | 83.42 |
| Previous Close | 83.36 |
| Day's Range | 82.11 - 84.13 |
| 52-Week Range | 58.10 - 121.06 |
| Beta | undefined |
About PCVX
Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company also develops VAX-XP to protect against emerging strains and address antibiotic resistance; VAX-A1, a co...
Industry Biotechnology
Sector Healthcare
IPO Date Jun 12, 2020
Employees 254
Stock Exchange NASDAQ
Ticker Symbol PCVX
Website https://vaxcyte.com
Analyst Forecast
According to 8 analyst ratings, the average rating for PCVX stock is "Buy." The 12-month stock price forecast is $146.5, which is an increase of 77.46% from the latest price.
Buy 100.00%
Hold 0.00%
Sell 0.00%
2 weeks ago
+3.26%
Vaxcyte shares are trading higher after the compan...
Unlock content with
Pro Subscription
3 months ago
-6.31%
Shares of vaccine stocks are trading lower After President-elect Trump nominated Robert F. Kennedy Jr. to lead the HHS.
